Why Are Tyme Technologies Shares Staring At 52-Week Low

TYME Technologies Inc TYME will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC).

  • The trial's sponsor, Pancreatic Cancer Action Network (PanCAN), terminated the arm due to futility compared to the control of the standard of care chemotherapy in second-line mPDAC. 
  • Based on the information provided by PanCAN, the overall survival for SM-88 with MPS in monotherapy was lower than the standard of care chemotherapies with either Gemcitabine and Abraxane or modified FOLFIRINOX.
  • The Precision Promise trial is an adaptive randomized Phase 2/3 trial in mPDAC for patients treated in both first-line and second-line therapies. 
  • SM-88 (racemetyrosine) with MPS (10 mg methoxsalen, 50 mg phenytoin, and 0.5 mg sirolimus) was the first therapy to join this trial and was being studied as a standalone monotherapy in second-line patients versus control arms of the standard of care regimens.
  • Price Action: TYME shares are down 41.1% at $0.31 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksShort IdeasHealth CareMoversTrading IdeasGeneralBriefsPhase 2 TrialPhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!